methylmalonic acid has been researched along with Hodgkin Disease in 1 studies
Methylmalonic Acid: A malonic acid derivative which is a vital intermediate in the metabolism of fat and protein. Abnormalities in methylmalonic acid metabolism lead to methylmalonic aciduria. This metabolic disease is attributed to a block in the enzymatic conversion of methylmalonyl CoA to succinyl CoA.
methylmalonic acid : A dicarboxylic acid that is malonic acid in which one of the methylene hydrogens is substituted by a methyl group.
Hodgkin Disease: A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Weight and methylmalonic acid (MMA) level were predictive of pharmacokinetic (PK) variability." | 1.35 | A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma. ( Duffull, SB; Fleisher, M; Hamlin, P; Horwitz, S; Mould, DR; Neylon, E; O'Connor, OA; Saunders, ME; Sirotnak, F; Sweeney, K, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mould, DR | 1 |
| Sweeney, K | 1 |
| Duffull, SB | 1 |
| Neylon, E | 1 |
| Hamlin, P | 1 |
| Horwitz, S | 1 |
| Sirotnak, F | 1 |
| Fleisher, M | 1 |
| Saunders, ME | 1 |
| O'Connor, OA | 1 |
1 other study available for methylmalonic acid and Hodgkin Disease
| Article | Year |
|---|---|
A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma.
Topics: Adult; Aged; Aminopterin; Antineoplastic Agents; Area Under Curve; Biomarkers; Body Size; Drug Admin | 2009 |